Rallybio Corp Stock Revenue
| RLYB Stock | USD 1.12 0.03 2.75% |
Rallybio Corp fundamentals help investors to digest information that contributes to Rallybio Corp's financial success or failures. It also enables traders to predict the movement of Rallybio Stock. The fundamental analysis module provides a way to measure Rallybio Corp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rallybio Corp stock.
| Last Reported | Projected for Next Year |
Rallybio | Revenue |
Rallybio Corp Company Revenue Analysis
Rallybio Corp's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Rallybio
Projected quarterly revenue analysis of Rallybio Corp provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Rallybio Corp match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Rallybio Corp's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Rallybio Corp reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Rallybio Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rallybio Corp's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rallybio Corp could also be used in its relative valuation, which is a method of valuing Rallybio Corp by comparing valuation metrics of similar companies.Rallybio Corp is currently under evaluation in revenue category among its peers.
Rallybio Corp Institutional Holders
Institutional Holdings refers to the ownership stake in Rallybio Corp that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Rallybio Corp's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rallybio Corp's value.| Shares | Millennium Management Llc | 2024-06-30 | 460 K | Mariner Wealth Advisors, Llc | 2024-06-30 | 405.6 K | Renaissance Technologies Corp | 2024-06-30 | 340.7 K | Blackrock Inc | 2024-06-30 | 315.6 K | Citadel Advisors Llc | 2024-06-30 | 280 K | Northern Trust Corp | 2024-06-30 | 228.9 K | Geode Capital Management, Llc | 2024-06-30 | 220 K | Goldman Sachs Group Inc | 2024-06-30 | 181.2 K | Almitas Capital Llc | 2024-06-30 | 100.9 K | Viking Global Investors Lp | 2024-06-30 | 4.2 M | Johnson & Johnson | 2024-06-30 | 3.6 M |
Rallybio Fundamentals
| Return On Equity | -0.67 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (56.97) % | ||||
| Current Valuation | (43.11 M) | ||||
| Shares Outstanding | 41.49 M | ||||
| Shares Owned By Insiders | 4.05 % | ||||
| Shares Owned By Institutions | 77.30 % | ||||
| Number Of Shares Shorted | 582.33 K | ||||
| Price To Book | 0.57 X | ||||
| Price To Sales | 151.94 X | ||||
| EBITDA | (78.78 M) | ||||
| Net Income | (74.56 M) | ||||
| Cash And Equivalents | 147.37 M | ||||
| Cash Per Share | 4.59 X | ||||
| Total Debt | 392 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.20 X | ||||
| Book Value Per Share | 1.93 X | ||||
| Cash Flow From Operations | (60.27 M) | ||||
| Short Ratio | 11.85 X | ||||
| Earnings Per Share | (1.79) X | ||||
| Target Price | 10.5 | ||||
| Number Of Employees | 25 | ||||
| Beta | -1.7 | ||||
| Market Capitalization | 45.43 M | ||||
| Total Asset | 115.62 M | ||||
| Retained Earnings | (235.25 M) | ||||
| Working Capital | 105.53 M | ||||
| Net Asset | 115.62 M |
About Rallybio Corp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rallybio Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rallybio Corp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rallybio Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Check out Rallybio Corp Piotroski F Score and Rallybio Corp Altman Z Score analysis. For information on how to trade Rallybio Stock refer to our How to Trade Rallybio Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rallybio Corp. If investors know Rallybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rallybio Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.79) | Revenue Per Share 0.007 | Return On Assets (0.39) | Return On Equity (0.67) |
The market value of Rallybio Corp is measured differently than its book value, which is the value of Rallybio that is recorded on the company's balance sheet. Investors also form their own opinion of Rallybio Corp's value that differs from its market value or its book value, called intrinsic value, which is Rallybio Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rallybio Corp's market value can be influenced by many factors that don't directly affect Rallybio Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rallybio Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rallybio Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rallybio Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.